XWELL (XWEL) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
1 Apr, 2026Executive summary
Revenue for 2025 was $29.2 million, down 14% year-over-year, mainly due to lower XpresTest segment revenues, partially offset by growth in Naples Wax Center services.
Operating loss for 2025 was $15.7 million, a slight improvement from $16.7 million in 2024, reflecting cost reductions and business optimization.
The company completed a major capital restructuring in early 2026, raising $31.3 million in gross proceeds through a private placement of Series H Preferred Stock and warrants, using $9 million to repurchase debt and preferred equity.
Management concluded that the new financing alleviated prior substantial doubt about the company's ability to continue as a going concern.
Financial highlights
Total revenue decreased by $4.7 million (14%) to $29.2 million in 2025, driven by a decline in XpresTest revenues.
Cost of sales decreased by $3.3 million (13%) to $21.7 million, reflecting closures of underperforming locations.
General and administrative expenses fell by $4.1 million (20%) to $16.0 million, due to cost optimization.
Impairment charges totaled $3.1 million for long-lived assets and $1.4 million for goodwill, primarily related to Naples Wax Center.
Net loss attributable to common stockholders was $28.2 million, or $5.08 per share, compared to $16.9 million, or $3.66 per share, in 2024.
Outlook and guidance
The company plans to expand and integrate offerings across brands, focusing on both airport and off-airport locations.
Strategic emphasis is on international expansion, membership programs, and off-airport growth through acquisitions, especially in the med spa sector.
Management expects the recent capital raise to provide sufficient liquidity for at least the next twelve months.
Latest events from XWELL
- Board recommends approval of all annual meeting proposals, including reverse split and share issuance.XWEL
Proxy Filing3 Feb 2026 - Annual meeting to vote on directors, auditor, executive pay, and tax asset protection plan.XWEL
Proxy Filing3 Feb 2026 - Board recommends voting for all proposals, including director elections and tax asset protection.XWEL
Proxy Filing3 Feb 2026 - Stockholders to vote on equity issuance, board structure, plan amendments, and auditor ratification.XWEL
Proxy Filing3 Feb 2026 - Registering 1,051,677 shares for resale may cause significant dilution to existing stockholders.XWEL
Registration Filing3 Feb 2026 - Registration of 32.7M shares may cause major dilution as the company expands wellness services.XWEL
Registration Filing3 Feb 2026 - Registration of 62M shares for resale may cause major dilution amid expansion and new contracts.XWEL
Registration Filing3 Feb 2026 - Virtual annual meeting to vote on directors, auditor, compensation, board structure, and stock split.XWEL
Proxy Filing3 Feb 2026 - Registration of 30.4M shares may cause major dilution and impact Nasdaq listing status.XWEL
Registration Filing3 Feb 2026